» Articles » PMID: 37410237

Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer

Overview
Specialty Molecular Biology
Date 2023 Jul 6
PMID 37410237
Authors
Affiliations
Soon will be listed here.
Abstract

Somatic mutations in the telomerase reverse transcriptase (TERT) promoter region are highly frequent in urothelial cancer (UC), and their detection in urine (cell-free DNA from the urine supernatant or DNA from exfoliated cells in the urine pellet) has demonstrated promising evidence as putative non-invasive biomarkers for UC detection and monitoring. However, detecting these tumour-derived mutations in urine requires highly sensitive methods, capable of measuring low-allelic fraction mutations. We developed sensitive droplet digital PCR (ddPCR) assays for detecting urinary TERT promoter mutations (uTERTpm), targeting the two most common mutations (C228T and C250T), as well as the rare A161C, C228A, and CC242-243TT mutations. Here, we described the step-by-step protocol uTERTpm mutation screening using simplex ddPCR assays and give some recommendations for isolation of DNA from urine samples. We also provide limits of detection for the two most frequent mutations and discuss advantages of the method for clinical implementation of the assays for the detection and monitoring of UC.

Citing Articles

Diagnostic performance of Uromonitor and TERTpm ddPCR urine tests for the non-invasive detection of bladder cancer.

Rabien A, Rong D, Rabenhorst S, Schlomm T, Labonte F, Hofbauer S Sci Rep. 2024; 14(1):30617.

PMID: 39715826 PMC: 11666540. DOI: 10.1038/s41598-024-83976-2.


Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials.

Huang F, Di X, Bai M Front Bioeng Biotechnol. 2024; 12:1458362.

PMID: 39295845 PMC: 11408225. DOI: 10.3389/fbioe.2024.1458362.


Novel method for detecting frequent TERT promoter hot spot mutations in bladder cancer samples.

Kovacs A, Sukosd F, Kuthi L, Boros I, Vedelek B Clin Exp Med. 2024; 24(1):192.

PMID: 39141194 PMC: 11324672. DOI: 10.1007/s10238-024-01464-3.

References
1.
Larre S, Catto J, Cookson M, Messing E, Shariat S, Soloway M . Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013; 63(6):1049-58. DOI: 10.1016/j.eururo.2012.12.062. View

2.
Schmitz-Drager B, Droller M, Lokeshwar V, Lotan Y, Hudson M, van Rhijn B . Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2014; 94(1):1-24. DOI: 10.1159/000369357. View

3.
Xylinas E, Kluth L, Rieken M, Karakiewicz P, Lotan Y, Shariat S . Urine markers for detection and surveillance of bladder cancer. Urol Oncol. 2013; 32(3):222-9. DOI: 10.1016/j.urolonc.2013.06.001. View

4.
Avogbe P, Manel A, Vian E, Durand G, Forey N, Voegele C . Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. EBioMedicine. 2019; 44:431-438. PMC: 6603852. DOI: 10.1016/j.ebiom.2019.05.004. View

5.
Olmedillas-Lopez S, Olivera-Salazar R, Garcia-Arranz M, Garcia-Olmo D . Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review. Mol Diagn Ther. 2021; 26(1):61-87. DOI: 10.1007/s40291-021-00562-2. View